evidencegaps
Primary study · included by 1 review

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma.

Lv 2022 · Lv Huilai, Tian Yang, Li Jiachen, et al. · Frontiers in oncology · 2022

Included by

The Efficacy and Safety of Neoadjuvant Immunotherapy in Pan-Squamous Cell Carcinomas: A Meta-Analysis of Esophageal, Head and Neck, Cervical, Lung, Cutaneous, and Oral Squamous Cell Carcinomas.
Non-Cochrane · intervention · 2026 · cited as Lv 2022 · Supplementary Table S1; reference list

The review does not say which of its outcomes this study informs.

1 including review in total.